Cargando…

Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19

BACKGROUND: Administration of Hydroxychloroquine and Azithromycin in patients with coronavirus disease 2019 (COVID-19) prolongs QTc corrected interval (QTc). The effect and safety of Lopinavir/Ritonavir in combination with these therapies have seldom been studied. OBJECTIVES: Our aim was to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Echarte-Morales, Julio, Minguito-Carazo, Carlos, del Castillo-García, Samuel, Borrego-Rodríguez, Javier, Rodríguez-Santamarta, Miguel, Sánchez-Muñoz, Enrique, Bergel-García, Rubén, González-Maniega, Clea, Prieto-González, Silvia, Menéndez-Suarez, Paula, Tundidor-Sanz, Elena, Benito-González, Tomás, Fernández-Vázquez, Felipe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698653/ https://www.ncbi.nlm.nih.gov/pubmed/33307378 http://dx.doi.org/10.1016/j.jelectrocard.2020.11.012

Ejemplares similares

QT Interval Monitoring with Handheld Heart Rhythm ECG Device in COVID-19 Patients
por: Minguito-Carazo, Carlos, et al.
Publicado: (2021)

Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients
por: Russo, Vincenzo, et al.
Publicado: (2020)

Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel
por: Zequn, Zheng, et al.
Publicado: (2021)

Afección cardiaca por COVID-19, ¿importa la ecocardiografía? Respuesta
por: Rodríguez-Santamarta, Miguel, et al.
Publicado: (2021)

Cardiac involvement in COVID-19: does echocardiography matter? Response
por: Rodríguez-Santamarta, Miguel, et al.
Publicado: (2021)

Azithromycin/hydroxychloroquine/lopinavir/ritonavir: Complete atrioventricular-block, torsades-de-pointes and QT-interval-prolongation following off label use: 2 case reports
Publicado: (2020)

Thrombus in transit through a patent foramen ovale: An unusual cause of cardiac embolism
por: Minguito-Carazo, Carlos, et al.
Publicado: (2020)

Azithromycin/hydroxychloroquine/lopinavir/ritonavir: Brugada-like ECG pattern following off-label use: case report
Publicado: (2021)

A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections
por: Purwati,, et al.
Publicado: (2021)

A case report of arterial and venous thromboembolism in a patient with severe COVID-19 pneumonia
por: Del Castillo-García, Samuel, et al.
Publicado: (2020)

Hydroxychloroquine/lopinavir/ritonavir: Exanthema and eosinophilia: 12 case reports
Publicado: (2020)

Dexamethasone/hydroxychloroquine/lopinavir/ritonavir: Various toxicities: case report
Publicado: (2021)

Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection
por: Moschini, Luigi, et al.
Publicado: (2020)

Hydroxychloroquine/lopinavir/ritonavir: Various side effects: 7 case reports
Publicado: (2020)

Hydroxychloroquine/lopinavir/ritonavir: Bradycardia and off-label-use: case report
Publicado: (2021)

QT interval prolongation with hydroxychloroquine plus azithromycin
Publicado: (2020)

Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome
por: Hraiech, Sami, et al.
Publicado: (2020)

Azithromycin/hydroxychloroquine: Prolongation of the QT interval: case report
Publicado: (2020)

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
por: Ader, Florence, et al.
Publicado: (2021)

Echocardiographic findings in critical patients with COVID-19
por: Rodríguez-Santamarta, Miguel, et al.
Publicado: (2020)

Hallazgos ecocardiográficos en pacientes críticos por COVID-19
por: Rodríguez-Santamarta, Miguel, et al.
Publicado: (2020)

Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients
por: Schneider, Johanna, et al.
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Guillain-Barre-syndrome and off-label-use: case report
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Lack of efficacy and off label use: 3 case reports
Publicado: (2022)

Hydroxychloroquine/lopinavir/ritonavir: Lack of efficacy following off-label use: case report
Publicado: (2022)

Azithromycin/lopinavir/ritonavir: Acute kidney injury following off label use: case report
Publicado: (2021)

“Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers
por: Gérard, Alexandre, et al.
Publicado: (2020)

An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results
por: Ader, Florence
Publicado: (2022)

Hydroxychloroquine/lopinavir/ritonavir/tocilizumab: Lack of efficacy following off label use: case report
Publicado: (2022)

Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with Moderate COVID-19, A Randomized, Double-blind Clinical Trial
por: Nekoukar, Zahra, et al.
Publicado: (2021)

Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19
por: O’Connell, Thomas F., et al.
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Acute generalised exanthematous pustulosis with erythema multiforme-like lesions: case report
Publicado: (2020)

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
por: Arabi, Yaseen M., et al.
Publicado: (2021)

A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19
por: Maciorowski, Dawid, et al.
Publicado: (2020)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

System biological investigations of hydroxychloroquine and azithromycin targets and their implications in QT interval prolongation
por: Khan, Abdul Arif, et al.
Publicado: (2020)

Azithromycin/hydroxychloroquine: QT prolongation following off label use: case report
Publicado: (2022)

THE EFFECT OF TREATMENT WITH HYDROXYCHLOROQUINE AND AZITHROMYCIN ON THE CORRECTED QT INTERVAL IN PATIENTS WITH COVID-19
por: Batemarco, Thomas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v4qgkgron2mbdmqq5t5be85jsf